Table of Contents 1.1 Objectives of this Document SECTION 2 – GENERAL TERM SELECTION PRINCIPLES 2.4 Always Select a Lowest Level Term 2.5 Select Only Current Lowest Level Terms 2.7 Use of Medical Judgment in Term Selection 2.8 Selecting More than One Term 2.10 Select Terms for All Reported Information, Do Not Add Information SECTION 3 – TERM SELECTION POINTS 3.1 Definitive and Provisional Diagnoses with or without Signs and Symptoms 3.2 Death and Other Patient Outcomes 3.2.2 Death as the only reported information 3.2.3 Death terms that add important clinical information 3.2.4 Other patient outcomes (non-fatal) 3.3.2 If self-injury is reported 3.4 Conflicting/Ambiguous/Vague Information 3.5.1 Diagnosis and sign/symptom 3.5.2 One reported condition is more specific than the other 3.5.3 A MedDRA combination term is available 3.5.4 When to “split” into more than one MedDRA term 3.5.5 Event reported with pre-existing condition 3.6.1 MedDRA term includes age and event information 3.6.2 No available MedDRA term includes both age and event information 3.7 Body Site vs. Event Specificity 3.7.1 MedDRA term includes body site and event information 3.7.2 No available MedDRA term includes both body site and event information 3.7.3 Event occurring at multiple body sites 3.8 Location-Specific vs. Microorganism-Specific Infection 3.8.1 MedDRA term includes microorganism and anatomic location 3.8.2 No available MedDRA term includes both microorganism and anatomic location 3.9 Modification of Pre-existing Conditions 3.10 Exposures during Pregnancy and Breast Feeding 3.10.2 Events in the child or foetus 3.11.2 Acquired conditions (not present at birth) 3.11.3 Conditions not specified as either congenital or acquired 3.12.1 Do not infer malignancy 3.13 Medical and Surgical Procedures 3.13.1 Only the procedure is reported 3.13.2 Procedure and diagnosis are reported 3.14.1 Results of investigations as ARs/AEs 3.14.2 Investigation results consistent with diagnosis 3.14.3 Investigation results not consistent with diagnosis 3.14.4 Grouped investigation result terms 3.14.5 Investigation terms without qualifiers 3.15 Medication Errors, Accidental Exposures and Occupational Exposures 3.15.2 Accidental exposures and occupational exposures 3.16 Misuse, Abuse and Addiction 3.17 Transmission of Infectious Agent via Product 3.18 Overdose, Toxicity and Poisoning 3.18.1 Overdose reported with clinical consequences 3.18.2 Overdose reported without clinical consequences 3.19.1 Device-related event reported with clinical consequences 3.19.2 Device-related event reported without clinical consequences 3.20.1 Reporter specifically states an interaction 3.20.2 Reporter does not specifically state an interaction 3.21 No Adverse Effect and “Normal” Terms 3.22 Unexpected Therapeutic Effect 3.23.2 Do not infer lack of effect 3.23.3 Increased, decreased and prolonged effect 3.24.1 Use of terms in this SOC 3.24.2 Illegal acts of crime or abuse 3.25 Medical and Social History 3.26 Indication for Product Use 3.26.3 Indications with genetic markers or abnormalities 3.26.4 Prevention and prophylaxis 3.26.5 Procedures and diagnostic tests as indications 3.26.6 Supplementation and replacement therapies 3.26.7 Indication not reported 3.27.1 Off label use when reported as an indication 3.27.2 Off label use when reported with an AR/AE 3.28.1 Product quality issue reported with clinical consequences 3.28.2 Product quality issue reported without clinical consequences 3.28.3 Product quality issue vs. medication error
|
MedDRA® TERM
SELECTION: ICH-Endorsed Guide for MedDRA Users Release 4.25
March 2025 Disclaimer and Copyright Notice This document is protected by copyright and may, with the exception of the MedDRA and ICH logos, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the document is acknowledged at all times. In case of any adaption, modification or translation of the document, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original document. Any impression that the adaption, modification or translation of the original document is endorsed or sponsored by the ICH must be avoided. The document is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original document be liable for any claim, damages or other liability arising from the use of the document. The above‑mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.
MedDRA® trademark is registered by ICH
SECTION 1 – INTRODUCTIONThe Medical Dictionary for Regulatory Activities terminology (MedDRA) was designed for sharing regulatory information for human medical products. In order for MedDRA to harmonise the exchange of coded data, users should be consistent in the assignment of terms to verbatim reports of symptoms, signs, diseases, etc. This MedDRA Term Selection: Points to Consider (MTS:PTC) document is an ICH-endorsed guide for MedDRA users. It is updated annually in step with the March release of MedDRA (starting with MedDRA Version 23.0) and is support documentation for MedDRA. It was developed and is maintained by a working group charged by the ICH Management Committee. The working group consists of representatives of ICH regulatory and industry members, the World Health Organization, the MedDRA Maintenance and Support Services Organization (MSSO), and the Japanese Maintenance Organization (JMO) (see the M1 MedDRA Terminology page under Multidisciplinary Guidelines on the ICH website for a list of current members). In addition, the working group has developed a condensed version of the MTS:PTC document which focuses on the fundamental principles of term selection and is intended to support the implementation and use of MedDRA in the ICH regions and beyond (see Appendix, Section 4.2). It is available in all MedDRA languages except for English, Japanese, and other languages with an available translation of the full MTS:PTC document. The full MTS:PTC document in its various translations will continue to be maintained and updated as the complete reference document. 1.1 Objectives of this DocumentThe objective of the MTS:PTC document is to promote accurate and consistent term selection. Organisations are encouraged to document their term selection methods and quality assurance procedures in organisation-specific coding guidelines which should be consistent with the MTS:PTC. Consistent term selection promotes medical accuracy for sharing MedDRA-coded data and facilitates a common understanding of shared data among academic, commercial and regulatory entities. The MTS:PTC could also be used by healthcare professionals, researchers, and other parties outside of the regulated biopharmaceutical industry. The document provides term selection considerations for business purposes and regulatory requirements. There may be examples that do not reflect practices and requirements in all regions. This document does not specify regulatory reporting requirements, nor does it address database issues. As experience with MedDRA increases, and as MedDRA changes, there will be revisions to this document. 1.2 Uses of MedDRATerm selection for adverse reactions/adverse events (ARs/AEs), device-related events, product quality issues, medication errors, exposures, medical history, social history, investigations, misuse and abuse, off label use, and indications is addressed in this MTS:PTC document. MedDRA's structure allows for aggregation of those reported terms in medically meaningful groupings to facilitate analysis of safety data. MedDRA can also be used to list AR/AE data in reports (tables, line listings, etc.), compute frequencies of similar ARs/AEs, and capture and analyse related data such as product indications, investigations, and medical and social history. 1.3 How to Use this DocumentThe MTS:PTC document does not address every potential term selection situation. Medical judgment and common sense should also be applied. This document is not a substitute for MedDRA training. It is essential for users to have knowledge of MedDRA's structure and content. For optimal MedDRA term selection, one should also refer to the MedDRA Introductory Guide (see Appendix, Section 4.2). Users are invited to contact the MSSO Help Desk with any questions or comments about this MTS:PTC document. 1.4 Preferred OptionIn some cases, where there is more than one option for selecting terms, a “preferred option” is identified in this document. Designation of a “preferred option” does not limit MedDRA users to applying that option. Users should always first consider regional regulatory requirements. An organisation should be consistent in the option that they choose to use and document that option in internal coding guidelines. 1.5 MedDRA Browsing ToolsThe MSSO provides browsers (the Desktop, Web-Based, and Mobile browsers) that allow for searching and viewing the terminology (see Appendix, Section 4.2). Users may find these browsers useful aids in term selection. SECTION 2 – GENERAL TERM SELECTION PRINCIPLES2.1 Quality of Source DataThe quality of the original reported information directly impacts the quality of data output. Clarification should be obtained for data that are ambiguous, confusing, or unintelligible. If clarification cannot be obtained, refer to Section 3.4. 2.2 Quality AssuranceTo promote consistency, organisations should document their term selection methods and quality assurance procedures in coding guidelines consistent with this MTS:PTC document. Clear initial data can be promoted through careful design of data collection forms, and training of individuals in data collection and follow-up (e.g., investigators, drug sales representatives). Term selection should be reviewed by a qualified individual, i.e., a person with medical background or training who has also received MedDRA training. Human oversight of term selection performed by IT tools (such as an autoencoder) is needed to assure that the end result fully reflects the reported information and makes medical sense. For further information, please refer to Section 2 of the MedDRA Points to Consider Companion Document which contains detailed examples and guidance on data quality (see Appendix, Section 4.2). 2.3 Do Not Alter MedDRAMedDRA is a standardised terminology with a pre-defined term hierarchy that should not be altered. Users must not make ad hoc structural alterations to MedDRA, including changing the primary SOC allocation; doing so would compromise the integrity of this standard. If terms are found to be incorrectly placed in the MedDRA hierarchy, a change request should be submitted to the MSSO. Example
2.4 Always Select a Lowest Level TermMedDRA Lowest Level Term(s) (LLT) that most accurately reflects the reported verbatim information should be selected. The degree of specificity of some MedDRA LLTs may be challenging for term selection. Here are some tips for specific instances: • A single letter difference in a reported verbatim text can impact the meaning of the word and consequently the term selection Example
• Gender-specific terms MedDRA generally excludes terms with demographic descriptors (age, gender, etc.), but some terms with gender qualifiers are included if the gender renders the concept unique. Example
Organisation-specific coding guidelines should address instances when it is important to capture gender-specific concepts. MedDRA users should also consider the impact of gender-specific terms when comparing current data to data coded with a legacy terminology in which such gender specificity may not have been available. Example
• Postoperative and post procedural terms MedDRA contains some “postoperative” and “post procedural” terms. Select the most specific term available. Example
• Newly added terms More specific LLTs may be available in a new version of MedDRA. See Appendix, Section 4.2. 2.5 Select Only Current Lowest Level TermsNon-current LLTs should not be used for term selection. 2.6 When to Request a TermDo not address deficiencies in MedDRA with organisation-specific solutions. If there is no MedDRA term available to adequately reflect the reported information, submit a change request to MSSO. Example
2.7 Use of Medical Judgment in Term SelectionIf an exact match cannot be found, medical judgment should be used to adequately represent the medical concept with an existing MedDRA term. 2.8 Selecting More than One TermWhen a specific medical concept is not represented by a single MedDRA term, consider requesting a new term through the change request process (see Section 2.6). Whilst waiting for the new term, select one or more existing terms using a consistent approach with careful consideration of the impact on data retrieval, analysis, and reporting. In some cases, it may be appropriate to select more than one MedDRA LLT to represent the reported information. If only one term is selected, specificity may be lost; on the other hand, selecting more than one term may lead to redundant counts. Established procedures should be documented. Example
2.9 Check the HierarchyWhen considering selecting an LLT, check the hierarchy above the LLT (PT level and further up the hierarchy to HLT, HLGT and SOC) to ensure the placement accurately reflects the meaning of the reported term. 2.10 Select Terms for All Reported Information, Do Not Add InformationSelect terms for every AR/AE reported, regardless of causal association. In addition, select terms for device-related events, product quality issues, medication errors, medical history, social history, investigations, and indications as appropriate. If a diagnosis is reported with characteristic signs and symptoms, the preferred option is to select a term for the diagnosis only (see Section 3.1 for details and examples). When selecting terms, no reported information should be excluded from the term selection process; similarly, do not add information by selecting a term for a diagnosis if only signs or symptoms are reported. Example
SECTION 3 – TERM SELECTION POINTS3.1 Definitive and Provisional Diagnoses with or without Signs and SymptomsThe table below provides term selection options for definitive and provisional diagnoses with or without signs/symptoms reported. Examples are listed below the table. A provisional diagnosis may be described as “suspicion of”, “probable”, “presumed”, likely”, “rule out”, “questionable”, “differential”, etc. The preferred option for a single or multiple provisional diagnosis(es) is to select a term(s) for the diagnosis(es) and terms for reported signs and symptoms. This is because a provisional diagnosis may change while signs/symptoms do not.
3.2 Death and Other Patient OutcomesDeath, disability, and hospitalisation are considered outcomes or seriousness criteria in the context of safety reporting and not usually considered ARs/AEs. Outcomes and seriousness criteria are typically recorded in a separate manner (data field) from AR/AE information. A term for the outcome or seriousness criterion should be selected if it is the only information reported or provides significant clinical information. (For reports of suicide and self-harm, see Section 3.3). 3.2.1 Death with ARs/AEsDeath is an outcome and seriousness criterion and is not usually considered an AR/AE. If ARs/AEs are reported along with death, select terms for the ARs/AEs. Record the fatal outcome in an appropriate data field. Example
3.2.2 Death as the only reported informationIf the only information reported is death, select the most specific death term available. Circumstances of death should not be inferred but recorded only if stated by the reporter. Death terms in MedDRA are linked to HLGT Fatal outcomes. Example
3.2.3 Death terms that add important clinical informationDeath terms that add important clinical information should be selected along with any reported ARs/AEs. Example
3.2.4 Other patient outcomes (non-fatal)Hospitalisation, disability, and other patient outcomes are not generally considered ARs/AEs. Example
If the only information reported is the patient outcome or seriousness criterion, select the most specific term available. Example
3.3 Suicide and Self-HarmAccurate and consistent term selection for reports of suicide attempts, completed suicides, and self-harm is necessary for data retrieval and analysis. If the motive for reported injury is not clear, seek clarification from the source. 3.3.1 If overdose is reportedDo not assume that an overdose – including an intentional overdose – is a suicide attempt. Select only the appropriate overdose term (see Section 3.18). 3.3.2 If self-injury is reportedFor reports of self-injury that do not mention suicide or suicide attempt, select only the appropriate self-injury term. Example
3.3.3 Fatal suicide attemptIf a suicide attempt is fatal, select the term that reflects the outcome instead of the attempt only. Example
3.4 Conflicting/Ambiguous/Vague InformationWhen conflicting, ambiguous, or vague information is reported, term selection to support appropriate data retrieval may be difficult. When this occurs, attempt to obtain more specific information. If clarification cannot be achieved, select terms as illustrated in the examples below (Sections 3.4.1 through 3.4.3). 3.4.1 Conflicting informationExample
3.4.2 Ambiguous informationExample
3.4.3 Vague informationFor information that is vague, attempt to obtain clarification. If clarification cannot be achieved, select an LLT that reflects the vague nature of the reported event. Example
3.5 Combination TermsA combination term in MedDRA is a single medical concept combined with additional medical wording that provides important information on pathophysiology or aetiology. A combination term is an internationally recognised, distinct and robust medical concept as illustrated in the examples below. Example
A combination term may be selected for certain reported ARs/AEs (e.g., a condition “due to” another condition), keeping the following points in mind (Note: medical judgment should be applied): 3.5.1 Diagnosis and sign/symptomIf a diagnosis and its characteristic signs or symptoms are reported, select a term for the diagnosis (see Section 3.1). A MedDRA combination term is not needed in this instance. Example
3.5.2 One reported condition is more specific than the otherIf two conditions are reported in combination, and one is more specific than the other, select a term for the more specific condition. Example
3.5.3 A MedDRA combination term is availableIf two conditions or concepts are reported in combination, and a single MedDRA combination term is available to represent them, select that term. Example
3.5.4 When to “split” into more than one MedDRA termIf “splitting” the reported ARs/AEs provides more clinical information, select more than one MedDRA term. For example, in the field of oncology, there may be situations in which it is important to capture information not only for the tumour type, but also for the associated genetic marker or abnormality because of the implications for aetiology, prognosis or treatment. If a combination term that describes a genetic marker or abnormality associated with a medical condition is not available, separate terms may be selected to represent the genetic marker or abnormality as well as the associated medical condition. Example
Exercise medical judgment so that information is not lost when “splitting” a reported term. Always check the MedDRA hierarchy above the selected term to be sure it is appropriate for the reported information. Example
3.5.5 Event reported with pre-existing conditionIf an event is reported along with a pre-existing condition that has not changed, and if there is not an appropriate combination term in MedDRA, select a term for the event only (see Section 3.9 for pre-existing conditions that have changed). Example
3.6 Age vs. Event Specificity3.6.1 MedDRA term includes age and event informationExample
3.6.2 No available MedDRA term includes both age and event informationThe preferred option is to select a term for the event and record the age in the appropriate demographic field. Alternatively, select terms (more than one) that together reflect both the age of the patient and the event. Example
3.7 Body Site vs. Event Specificity3.7.1 MedDRA term includes body site and event informationExample
3.7.2 No available MedDRA term includes both body site and event informationSelect a term for the event, rather than a term that reflects a non-specific condition at the body site; in other words, the event information generally has priority. Example
However, medical judgment is required, and sometimes, the body site information should have priority as in the example below. Example
3.7.3 Event occurring at multiple body sitesIf an event is reported to occur at more than one body site, and if all of those LLTs link to the same PT, then select a single LLT that most accurately reflects the event; in other words, the event information has priority. Example
3.8 Location-Specific vs. Microorganism-Specific Infection3.8.1 MedDRA term includes microorganism and anatomic locationExample
3.8.2 No available MedDRA term includes both microorganism and anatomic locationThe preferred option is to select terms for both the microorganism-specific infection and the anatomic location. Alternatively, select a term that reflects the anatomic location or select a term that reflects the microorganism-specific infection. Medical judgment should be used in deciding whether anatomic location or the microorganism-specific infection should take priority. Example
3.9 Modification of Pre-existing ConditionsPre-existing conditions that have changed may be considered ARs/AEs, especially if the condition has worsened or progressed (see Section 3.5.5 for pre-existing conditions that have not changed, and Section 3.22 for an unexpected improvement of a pre-existing condition).
Select a term that most accurately reflects the modified condition (if such term exists) Example
If no such term exists, consider these approaches: • Example 1: Select a term for the pre-existing condition and record the modification in a consistent, documented way in appropriate data fields • Example 2: Select a term for the pre-existing condition and a second term for the modification of the condition (e.g., LLT Condition aggravated, LLT Disease progression). Record the modification in a consistent, documented way in appropriate data fields. Example
3.10 Exposures during Pregnancy and Breast FeedingTo select the most appropriate exposure term (or terms) from HLT Exposures associated with pregnancy, delivery and lactation , first determine if the subject/patient who was exposed is the mother, the child/foetus, or the father. If the reported verbatim information does not specify who was exposed, then a general term such as LLT Exposure during pregnancy can be selected. In addition, MedDRA includes terms indicating a pregnant or breastfeeding woman was exposed, which are placed in HLTs other than HLT Exposures associated with pregnancy, delivery and lactation . These terms include e.g., PT Maternal immunisation , PT Maternal therapy to enhance foetal lung maturity and PT Maternal-foetal therapy , as well as several PTs relating to pregnancy on contraceptive. Selecting pregnancy/breast-feeding exposure terms may be considered in addition, depending on the specific circumstances of each case. 3.10.1 Events in the mother3.10.1.1 Pregnant patient exposed to medication with clinical consequencesIf a pregnancy exposure is reported with clinical consequences, select terms for both the pregnancy exposure and the clinical consequences. Example
3.10.1.2 Pregnant patient exposed to medication without clinical consequencesIf a pregnancy exposure report specifically states that there were no clinical consequences, the preferred option is to select only a term for the pregnancy exposure. Alternatively, a term for the pregnancy exposure and the additional LLT No adverse effect can be selected (see Section 3.21). Example
3.10.2 Events in the child or foetusSelect terms for both the type of exposure and any adverse event(s). Example
3.11 Congenital Terms“Congenital” = any condition present at birth, whether genetically inherited or occurring in utero (see the MedDRA Introductory Guide). 3.11.1 Congenital conditionsSelect terms from SOC Congenital, familial and genetic disorders when the reporter describes the condition as congenital or when medical judgment establishes that the condition was present at the time of birth. Example
3.11.2 Acquired conditions (not present at birth)If information is available indicating that the condition is not congenital or present at birth, i.e., it is acquired, select the non-qualified term for the condition, making sure that the non-qualified term does not link to SOC Congenital, familial and genetic disorders . If a non-qualified term is not available, select the “acquired” term for the condition. Example
3.11.3 Conditions not specified as either congenital or acquiredIf a condition is reported without any information describing it as congenital or acquired, select the non-qualified term for the condition. For conditions or diseases existing in both congenital and acquired forms, the following convention is applied in MedDRA: the more common form of the condition/disease is represented at the PT level without adding a qualifier of either “congenital” or “acquired”. Example
3.12 NeoplasmsDue to the large number of neoplasm types, specific guidance cannot be provided for all situations. The MedDRA Introductory Guide describes the use and placement of neoplasm terms and related terms in MedDRA. Keep in mind the following points:
If the type of neoplasia is not clear, seek clarification from the reporter. Consult medical experts when selecting terms for difficult or unusual neoplasms. 3.12.1 Do not infer malignancySelect a malignancy term only if malignancy is stated by the reporter. Reports of “tumo(u)r” events should not be assigned a “cancer”, “carcinoma” or another malignant term unless it is clear that malignancy is present. Example
3.13 Medical and Surgical ProceduresTerms in SOC Surgical and medical procedures are generally not appropriate for ARs/AEs. Terms in this SOC are not multiaxial. Be aware of the impact of these terms on data retrieval, analysis, and reporting. Keep in mind the following points: 3.13.1 Only the procedure is reportedIf only a procedure is reported, select a term for the procedure. Example
3.13.2 Procedure and diagnosis are reportedIf a procedure is reported with a diagnosis, the preferred option is to select terms for both the procedure and diagnosis. Alternatively, select a term only for the diagnosis. Example
3.14 InvestigationsSOC Investigations includes test names with qualifiers (e.g., increased, decreased, abnormal, normal) and without qualifiers. Corresponding medical conditions (such as “hyper-” and “hypo-” terms) are in other “disorder” SOCs (e.g., SOC Metabolism and nutrition disorders). SOC Investigations is not multiaxial; always consider the terms in this SOC for data retrieval. 3.14.1 Results of investigations as ARs/AEsKeep in mind the following points when selecting terms for results of investigations: • Selecting terms for a medical condition vs. an investigation result Example
• Unambiguous investigation result Example
• Ambiguous investigation result Example
3.14.2 Investigation results consistent with diagnosisWhen investigation results are reported with a diagnosis, select only a term for the diagnosis if investigation results are consistent with the diagnosis. Example
3.14.3 Investigation results not consistent with diagnosisWhen investigation results are reported with a diagnosis, select a term for the diagnosis and also select terms for any investigation results that are not consistent with the diagnosis. Example
3.14.4 Grouped investigation result termsSelect a term for each investigation result as reported; do not “lump” together separate investigation results under an inclusive term unless reported as such. Example
3.14.5 Investigation terms without qualifiersTerms in SOC Investigations without qualifiers are intended to be used to record test names when entering diagnostic test data in the ICH E2B electronic transmission standard. Example
* MedDRA is used only for test names, not test results, in the E2B data elements for Results of Tests and Procedures
Test name terms without qualifiers are not intended for use in other data fields capturing information such as ARs/AEs and medical history. The use of the Unqualified Test Name Term List is optional and may be used to identify the inappropriate selection of these terms in data fields other than the test name data element. It is available for download from the MedDRA and JMO websites. 3.15 Medication Errors, Accidental Exposures and Occupational Exposures3.15.1 Medication errorsFor the purposes of term selection and analysis of MedDRA-coded data, medication errors are defined as any unintentional and preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient or consumer. The online Concept Descriptions contain descriptions of the interpretation and use of certain medication error terms (e.g., “Dispensing error”). For further information, please refer to Section 3 of the MedDRA Points to Consider Companion Document which contains detailed examples, guidance, and “Questions and Answers” on medication errors (see Appendix, Section 4.2 Links and References). Reports of medication errors may or may not include information about clinical consequences. 3.15.1.1 Medication errors reported with clinical consequencesIf a medication error is reported with clinical consequences, select terms for both the medication error and the clinical consequences. Example
3.15.1.2 Medication errors and potential medication errors reported without clinical consequencesMedication errors without clinical consequences are not ARs/AEs. However, it is important to record the occurrence or potential occurrence of a medication error. Select a term that is closest to the description of medication error reported. Intercepted medication error : For the purposes of term selection and analysis of MedDRA-coded data, an intercepted medication error refers to the situation where a medication error has occurred, but is prevented from reaching the patient or consumer. The intercepted error term should reflect the stage at which the error occurred, rather than the stage at which it was intercepted. If a medication error report specifically states that there were no clinical consequences, the preferred option is to select only a term for the medication error. Alternatively, a term for the medication error and the additional LLT No adverse effect can be selected (see Section 3.21). Example
Example
3.15.1.3 Medication monitoring errorsFor the purposes of term selection and analysis of MedDRA-coded data, a medication monitoring error is an error that occurs in the process of monitoring the effect of the medication through clinical assessment and/or laboratory data. It can also refer to monitoring errors in following instructions or information pertinent to the safe use of the medication, such as the specific scenario regarding the term LLT Documented hypersensitivity to administered drug in the example below. Example
Example
There are specific medication error situations when the product is prescribed, dispensed, or co-administered with specific drugs, with specific foods, or to patients with specific disease states, or genetic variants, and the product label describes known noxious effects of these interactions. Select a medication error term for the type of interaction, such as those listed below. If the report indicates that this is intentional misuse or intentional off label use, select the appropriate terms representing the intentional nature of the event. If the report does not provide information about whether the event was accidental or intentional, select an appropriate interaction issue term, e.g., LLT Labelled drug-drug interaction issue .
Example
3.15.1.4 Do not infer a medication errorDo not infer that a medication error has occurred unless specific information is provided. This includes inferring that extra dosing, overdose, or underdose has occurred (see Section 3.18). Example
3.15.2 Accidental exposures and occupational exposures3.15.2.1 Accidental exposuresThe principles for Section 3.15.1 (Medication errors) also apply to accidental exposures. Example
3.15.2.2 Occupational exposuresFor the purposes of term selection and analysis of MedDRA-coded data, occupational exposure encompasses the “chronic” exposure to an agent (including therapeutic products) during the normal course of one's occupation, and could include additional scenarios in specific regulatory regions. For example, occupational exposure may additionally relate to a more acute, accidental form of exposure that occurs in the context of one's occupation. In these regions, occupational exposure for healthcare workers could be of particular interest. Example
3.16 Misuse, Abuse and AddictionThe concepts of misuse, abuse and addiction are closely related and can pose challenges for term selection since the terms may overlap to some extent; the specific circumstances of each case/reported event may help in consideration for term selection of these concepts. Medical judgment and regional regulatory considerations need to be applied. It may also be useful to consider these concepts as shown in the table below:
* Definitions of misuse may not always include the concept of therapeutic use; misuse may be similar to the concept of abuse in some regions. Select the most specific term available and always check the MedDRA hierarchy above the selected term to be sure it is appropriate for the reported information. In some cases, it may be appropriate to select more than one MedDRA LLT to represent the reported information. 3.16.1 MisuseFor the purposes of term selection and analysis of MedDRA-coded data, misuse is the intentional use for a therapeutic purpose by a patient or consumer of a product–over-the-counter or prescription – other than as prescribed or not in accordance with the authorised product information. Example
3.16.2 AbuseFor the purposes of term selection and analysis of MedDRA-coded data, abuse is the intentional, non-therapeutic use by a patient or consumer of a product – over-the counter or prescription – for a perceived reward or desired non‑therapeutic effect including, but not limited to, “getting high” (euphoria). Abuse may occur with a single use, sporadic use or persistent use of the product. Example
See Section 3.24.1 and 3.24.2 for additional references to “abuse” terms in MedDRA. 3.16.3 AddictionFor the purposes of term selection and analysis of MedDRA-coded data, addiction is an overwhelming desire by a patient or consumer to take a drug for non-therapeutic purposes together with inability to control or stop its use despite harmful consequences. Addiction can occur because drug induces physical dependence and consequently a withdrawal syndrome, but this is not an essential feature; and addiction can occur because of a desire to experience the drug's psychological, behavioural or physical effects. Example
See Section 3.24.1 for additional references to “addict/addiction” terms in MedDRA. 3.16.4 Drug diversionFor the purposes of term selection and analysis of MedDRA-coded data, drug diversion means that a drug is diverted from legal and medically necessary uses toward illegal uses. Example
3.17 Transmission of Infectious Agent via ProductIf a report of transmission of an infectious agent via a product is received, select a term for the transmission. If the infection is identified, select a second term for the specific infection; if appropriate, a product quality issue term can also be selected (see Section 3.28). Example
Medical judgment should be used if the reporter does not explicitly state transmission of an infectious agent via a product but this could be implied by other data within the report. In this instance, select LLT Suspected transmission of an infectious agent via product . 3.18 Overdose, Toxicity and PoisoningAccidental overdose terms are grouped under HLT Product administration errors and issues; other overdose terms are grouped under HLT Overdoses NEC. Toxicity and poisoning terms are grouped under HLT Poisoning and toxicity . For the purposes of term selection and analysis of MedDRA-coded data, overdose is more than the maximum recommended dose (in quantity and/or concentration), i.e., an excessive dose (see online Concept Descriptions.) If overdose, poisoning or toxicity is explicitly reported, select the appropriate term. Example
3.18.1 Overdose reported with clinical consequencesSelect terms for overdose and for clinical consequences reported in association with an overdose. Example
3.18.2 Overdose reported without clinical consequencesIf an overdose report specifically states that there were no clinical consequences, the preferred option is to select only a term for the overdose. Alternatively, a term for the overdose and the additional LLT No adverse effect can be selected (see Section 3.21). Example
3.19 Device-related Terms3.19.1 Device-related event reported with clinical consequencesIf available, select a term that reflects both the device-related event and the clinical consequence, if so reported. Example
If there is no single MedDRA term reflecting the device-related event and the clinical consequence, select separate terms for both. Example
3.19.2 Device-related event reported without clinical consequencesIf a device-related event is reported in the absence of clinical consequences, select the appropriate term. Example
3.20 Drug InteractionsThis term includes reactions between drugs and other drugs, food, devices and alcohol. In this document, “drug” includes biologic products. Labelled drug interactions may be medication errors (see Section 3.15.1.3). 3.20.1 Reporter specifically states an interactionSelect an interaction term and additional term(s) for any reported medical event. Example
3.20.2 Reporter does not specifically state an interactionTwo products may be used together, but if the reporter does not specifically state that an interaction has occurred, select terms only for the medical events reported. Example
3.21 No Adverse Effect and “Normal” Terms3.21.1 No adverse effectLLT No adverse effect can be used when absence of an AR/AE is specifically reported, despite exposure to a product (see Sections 3.15.1.2 and 3.18.2). Some organisations may want to record LLT No adverse effect for administrative purposes (e.g., pregnancy registries, overdose and medication error reports). 3.21.2 Use of “normal” termsTerms for normal states and outcomes can be used as needed.
3.22 Unexpected Therapeutic EffectSome organisations may want to record reports of a beneficial effect of a product apart from the reason it had been given. (Such effects are not usually considered ARs/AEs). Example
3.23 Modification of EffectIt is important to record modification of effect (e.g., increased, prolonged) although it is not always an AR/AE. 3.23.1 Lack of effectThe preferred option is to select only the “lack of effect” term even if consequences are also reported. However, terms may also be selected for events associated with the lack of effect. Example
3.23.2 Do not infer lack of effectExample
3.23.3 Increased, decreased and prolonged effectExample
3.24 Social Circumstances3.24.1 Use of terms in this SOCTerms in SOC Social circumstances represent social factors and may be suitable to record social and medical history data. Such terms are not generally suitable for recording ARs/AEs; however, in certain instances, terms in SOC Social circumstances are the only available terms for recording ARs/AEs or may add valuable clinical information. Example
Terms in SOC Social circumstances are not multiaxial and, unlike terms in other “disorder” SOCs in MedDRA (e.g., SOC Gastrointestinal disorders), they generally refer to a person, not to a medical condition. Be aware of the impact that terms in SOC Social circumstances may have on data retrieval, analysis and reporting as illustrated in the table below:
Note that “abuse” terms not associated with drugs/substances are in this SOC, regardless of whether they refer to the person or to the condition, as illustrated in the table below:
(See Section 3.24.2 concerning illegal/criminal acts.) 3.24.2 Illegal acts of crime or abuseTerms for illegal acts of crime and abuse (excluding those related to drug/substance abuse) are in SOC Social circumstances, such as LLT Physical assault. LLTs representing the perpetrator are linked to PTs describing the unlawful act committed. PTs representing the victim of unlawful acts generally begin with “Victim of… ”. Example
3.25 Medical and Social HistoryExample
3.26 Indication for Product UseIndications can be reported as medical conditions, prophylaxis of conditions, replacement therapies, procedures (such as anaesthesia induction) and verbatim terms such as “anti-hypertension”. Terms from almost any MedDRA SOC – including SOC Investigations – may be selected to record indications. Regulatory authorities may have specific requirements for certain aspects of term selection for indications (e.g., for indications within regulated product information). Please refer to the regulatory authority's specific guidance for such issues. 3.26.1 Medical conditionsExample
If the only information reported is the type of therapy, select the most specific term. Example
It may not be clear if the reported indication is a medical condition or a desired outcome of therapy. The term selected in either case may be the same. Example
3.26.2 Complex indicationsTerm selection for some indications (e.g., in regulated product information) may be complex and require selection of more than one LLT to represent the information completely, depending on the circumstances. Example
3.26.3 Indications with genetic markers or abnormalitiesFor indications that describe a genetic marker or abnormality associated with a medical condition, select a combination term that represents both concepts, if available. See also examples in Section 3.5 Combination Terms. Example
3.26.4 Prevention and prophylaxisWhen an indication for prevention or prophylaxis is reported, select the specific MedDRA term, if it exists (Note: the words “prevention” and “prophylaxis” are synonymous in the context of MedDRA). Example
If there is no MedDRA term containing “prevention” or “prophylaxis”, choose one of the following options. The preferred option is to select a general prevention/ prophylaxis term and a term for the condition. Alternatively, select a term for the condition alone or a prevention/prophylaxis term alone. Example
3.26.5 Procedures and diagnostic tests as indicationsSelect the appropriate term if the product is indicated for performing a procedure or a diagnostic test. Example
3.26.6 Supplementation and replacement therapiesTerms for supplemental and replacement therapies are in SOC Surgical and medical procedures (see Section 3.13). If the product indication is for supplementation or replacement therapy, select the closest term. Example
3.26.7 Indication not reportedIf clarification cannot be obtained, select LLT Drug use for unknown indication. Example
3.27 Off Label UseFor the purposes of term selection and analysis of MedDRA-coded data, the concept of “off label use” relates to situations where a healthcare professional intentionally prescribes, dispenses, or recommends a product for a medical purpose not in accordance with the authorised product information (Consider also the table in Section 3.16). Off label use terms should only be selected when off label use is specifically mentioned in the reported verbatim information. For information that is suggestive of off label use but not reported, attempt to obtain clarification. If clarification cannot be obtained, do not infer that off label use occurred. When recording off label use, consider that product information and/or regulations/requirements may differ between regulatory regions. 3.27.1 Off label use when reported as an indicationIf a medical condition/indication is reported along with “off label use” , the preferred option is to select terms for the medical condition/indication and off label use. Alternatively, select a term for the medical condition/indication alone. Select LLT Off label use alone only if it is the only information available. Example
Example
Example
3.27.2 Off label use when reported with an AR/AEIf an AR/AE occurs in the setting of off label use for a medical condition/indication, the preferred option is to select a term for off label use, and a term for the medical condition/indication in addition to a term for the AR/AE. Alternatively, select a term for the medical condition/indication and a term for the AR/AE. Example
3.28 Product Quality IssuesIt is important to recognise product quality issues as they may have implications for patient safety. They may be reported in the context of adverse events or as part of a product quality monitoring system. Product quality issues are defined as abnormalities that may be introduced during the manufacturing/labelling, packaging, shipping, handling or storage of the products. They may occur with or without clinical consequences. Such concepts may pose a challenge for term selection. Familiarity with HLGT Product quality, supply, distribution, manufacturing and quality system issues (in SOC Product issues) is essential for term selection. Under this HLGT are categories of specific product quality issues such as HLT Product packaging issues, HLT Product physical issues, HLT Manufacturing facilities and equipment issues , HLT Counterfeit, falsified and substandard products , etc. Navigating down to the appropriate LLTs from the MedDRA hierarchy is the optimal approach for term selection. Explanations of the interpretations and uses of certain product quality issue terms (e.g., “Product coating incomplete”) are found in the online MedDRA Concept Descriptions. 3.28.1 Product quality issue reported with clinical consequencesIf a product quality issue results in clinical consequences, term(s) for the product quality issue and the clinical consequences should be selected. Example
3.28.2 Product quality issue reported without clinical consequencesIt is important to capture the occurrence of product quality issues even in the absence of clinical consequences. Example
3.28.3 Product quality issue vs. medication errorIt is important to distinguish between a product quality issue and a medication error. Product quality issues are defined as abnormalities that may be introduced during the manufacturing/labelling, packaging, shipping, handling or storage of the products. They may occur with or without clinical consequences. Medication errors are defined as any unintentional and preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient or consumer. Explanations of the interpretations of product quality issue terms are found in the online Concept Descriptions. Example
SECTION 4 – APPENDIX4.1 VersioningPlease refer to the most recent version of the MedDRA Best Practices document for information on versioning. 4.2 Links and ReferencesThe following documents and tools can be found on the MedDRA website: (www.meddra.org): • MedDRA Term Selection: Points to Consider Condensed Version • MedDRA Data Retrieval and Presentation: Points to Consider document (also available on the JMO website: www.pmrj.jp/jmo/) • MedDRA Data Retrieval and Presentation: Points to Consider Condensed Version • MedDRA Points to Consider Companion Document (also available on the JMO website: www.pmrj.jp/jmo/) • MedDRA Introductory Guide • MedDRA Change Request Information document • MedDRA Web-Based Browser * • MedDRA Mobile Browser * • MedDRA Desktop Browser • MedDRA Version Report (lists all changes in new version) * • MedDRA Version Analysis Tool (compares any two versions) * • Unqualified Test Name Term List • MedDRA Best Practices • Transition Date for the Next MedDRA Version * Requires user ID and password to access |